BioFragment specializes in sustainable biocatalysis for drug fragment and small molecule hydroxylation, providing tailored enzyme-based synthesis that enhances scalability and efficiency in pharmaceutical manufacturing. The company addresses the need for environmentally-friendly processes in drug development, minimizing the ecological impact while improving safety and diversity in drug synthesis.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional chemical synthesis methods for drug fragments and small molecules often rely on harsh reagents, generate significant waste, and lack stereoselectivity, leading to complex purification processes and environmental concerns. These limitations hinder the efficient and sustainable production of diverse chemical libraries for drug discovery.
Solution
BioFragment offers a biocatalysis platform for drug fragment and small molecule hydroxylation, providing an alternative to traditional chemical synthesis. Their enzyme-based approach enables scalable, stereoselective, and sustainable production of diverse chemical libraries. By leveraging biocatalysis, BioFragment minimizes environmental impact, enhances safety, and improves efficiency in pharmaceutical manufacturing, offering tailored solutions to meet specific research needs.
Target Audience
BioFragment's primary customers are pharmaceutical companies, drug discovery research labs, and chemical synthesis organizations seeking sustainable and efficient methods for producing drug fragments and small molecules.
Features
- Tailored enzyme-based synthesis for drug fragment and small molecule hydroxylation
- Scalable biocatalytic processes for efficient production of chemical libraries
- Stereoselective hydroxylation reactions for enhanced product purity
- Sustainable and environmentally-friendly alternative to traditional chemical synthesis
- Fragment Customisation services to meet specific research needs
- Fragment Library of diverse chemical building blocks
- Consulting services for biocatalysis implementation